Cytokinetics, Incorporated - Common Stock (CYTK)

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.